FOLH1 and prostate carcinoma: PSMA-targeted drug-loaded polymersomes containing a histone deacetylase inhibitor (mocetinostat) and an anticancer drug (docetaxel) have been shown to be promising options for enhancing prostate cancer therapy by reducing systemic toxicity and maximizing the efficiency of drug delivery (Karandish et al. 2016).